Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

NCT02393625 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

ALK-positive NSCLC

Interventions

DRUG: Ceritinib (LDK378)
DRUG: Nivolumab

Sponsor

Novartis Pharmaceuticals